ATE499934T1 - Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs - Google Patents
Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebsInfo
- Publication number
- ATE499934T1 ATE499934T1 AT04776757T AT04776757T ATE499934T1 AT E499934 T1 ATE499934 T1 AT E499934T1 AT 04776757 T AT04776757 T AT 04776757T AT 04776757 T AT04776757 T AT 04776757T AT E499934 T1 ATE499934 T1 AT E499934T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- analogues
- treatment
- heterocyclic compounds
- animal
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 abstract 3
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241000283984 Rodentia Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48027003P | 2003-06-20 | 2003-06-20 | |
| US56695204P | 2004-04-30 | 2004-04-30 | |
| PCT/US2004/019543 WO2005002572A2 (en) | 2003-06-20 | 2004-06-18 | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE499934T1 true ATE499934T1 (de) | 2011-03-15 |
Family
ID=33567612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04776757T ATE499934T1 (de) | 2003-06-20 | 2004-06-18 | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20050049294A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1638552B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2007523862A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20060026052A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102151261A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE499934T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004253478A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0411677A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2532066C (cg-RX-API-DMAC7.html) |
| DE (1) | DE602004031614D1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL172705A (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05013982A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ544588A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005002572A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2402045T3 (es) * | 2000-11-16 | 2013-04-26 | The Regents Of The University Of California | Taxón de actionomiceto marino para el descubrimiento de fármacos y de productos de fermentación |
| US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
| US7179834B2 (en) * | 2002-06-24 | 2007-02-20 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
| JP2007523862A (ja) * | 2003-06-20 | 2007-08-23 | ネレアス ファーマシューティカルズ インコーポレイテッド | 癌、炎症及び感染性疾患の治療のための、[3.2.0]複素環式化合物およびそれらの類縁体の使用 |
| US8217072B2 (en) | 2003-06-20 | 2012-07-10 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
| JP4691041B2 (ja) | 2003-11-20 | 2011-06-01 | チルドレンズ ホスピタル メディカル センター | Gtpアーゼ阻害剤および使用方法 |
| WO2005099687A2 (en) * | 2004-04-09 | 2005-10-27 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
| US7276530B2 (en) * | 2004-04-30 | 2007-10-02 | Nereus Pharmaceuticals, Inc. | [3.2.0] Heterocyclic compounds and methods of using the same |
| US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
| EP1771411A1 (en) * | 2004-07-12 | 2007-04-11 | Bayer CropScience Aktiengesellschaft | Substituted 2-pyrrolidone derivatives as fungicides and insecticides |
| CN103230394B (zh) * | 2004-12-03 | 2016-04-20 | 达纳-法伯癌症研究公司 | 治疗肿瘤性疾病的化合物及其用途 |
| JP2008522975A (ja) * | 2004-12-03 | 2008-07-03 | ネレアス ファーマシューティカルズ インコーポレイテッド | [3.2.0]複素環式化合物及びそれらのアナログを使用する方法 |
| WO2007016539A2 (en) | 2005-07-29 | 2007-02-08 | Children's Hospital Medical Center | Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase |
| US7691896B2 (en) | 2005-08-10 | 2010-04-06 | President And Fellows Of Harvard College | Analogs of salinosporamide A |
| WO2007021897A1 (en) * | 2005-08-10 | 2007-02-22 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
| WO2007030662A1 (en) * | 2005-09-09 | 2007-03-15 | Nereus Pharmaceuticals, Inc. | Biosynthesis of salinosporamide a and its analogs |
| US7465720B2 (en) * | 2005-09-12 | 2008-12-16 | President And Fellows Of Harvard College | Proteasome inhibiting β-lactam compounds |
| CA2628110A1 (en) * | 2005-11-04 | 2007-05-18 | The Regents Of The University Of California | Methods of sensitizing cancer to therapy-induced cytotoxicity |
| NZ596653A (en) * | 2006-04-06 | 2012-10-26 | Nereus Pharmaceuticals Inc | Total synthesis of salinosporamide a and analogs thereof |
| WO2008097249A2 (en) * | 2006-06-14 | 2008-08-14 | Children's Medical Center Corporation | Method for the treatment of anthrax toxicity |
| US8986971B2 (en) | 2006-09-22 | 2015-03-24 | Triphase Research And Development I Corp. | Salt formulations for the fermentation of marine microorganisms |
| WO2008095195A2 (en) | 2007-02-02 | 2008-08-07 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of salinosporamide a |
| WO2008137780A2 (en) * | 2007-05-04 | 2008-11-13 | Nereus Pharmaceuticals, Inc. | Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
| US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
| EP2088205A1 (en) | 2008-02-11 | 2009-08-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | PSMB10: A diagnosis marker and therapeutic target of chronic rejection. |
| BRPI0909661A2 (pt) | 2008-03-07 | 2015-08-11 | Nereus Pharmaceuticals Inc | Composto e métodos de síntese química e de formação ou preparação de compostos |
| US20090285836A1 (en) * | 2008-04-14 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Use of salinosporamide a to inhibit metastasis |
| US7910616B2 (en) | 2008-05-12 | 2011-03-22 | Nereus Pharmaceuticals, Inc. | Proteasome inhibitors |
| US20110111417A1 (en) | 2008-05-14 | 2011-05-12 | Millennium Pharmaceuticals, Inc. | Methods and kits for monitoring the effects of immunomodulators on adaptive immunity |
| US8321151B2 (en) | 2008-12-30 | 2012-11-27 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
| US8073632B2 (en) * | 2008-12-30 | 2011-12-06 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
| US8315815B2 (en) | 2008-12-30 | 2012-11-20 | The Invention Science Fund I, Llc | Computational methods and systems for suggesting modulators of CYP450 as treatment options |
| EP2399129B1 (en) | 2009-02-20 | 2015-11-25 | Michael P. Lisanti | A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm |
| US9126997B1 (en) | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
| WO2012135528A2 (en) * | 2011-03-29 | 2012-10-04 | Texas Tech University System | Galectin-3c combination therapy for human cancer |
| CA2862580A1 (en) | 2011-10-28 | 2013-05-02 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to nae inhibitors |
| EP2776586B1 (en) | 2011-11-11 | 2018-03-07 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| WO2013112601A1 (en) | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
| GB2523211B (en) | 2012-01-27 | 2020-03-18 | Univ Jefferson | MCT protein inhibitor-related prognostic and therapeutic methods |
| US10662477B2 (en) | 2012-10-01 | 2020-05-26 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods to predict response to inhibitors and uses thereof |
| EA201590916A1 (ru) | 2012-11-09 | 2016-02-29 | Корнэлл Юниверсити | Низкомолекулярные ингибиторы malt1 |
| EP2986290A4 (en) | 2013-04-19 | 2017-01-04 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
| US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
| ES2984487T3 (es) | 2016-06-01 | 2024-10-29 | Celgene Tri A Holdings Ltd | Uso combinado de marizomib y bevacizumab para el tratamiento de cánceres del sistema nervioso central (SNC) |
| US10703760B2 (en) | 2016-08-19 | 2020-07-07 | Celgene International Ii Sàrl | Morphic forms of marizomib and uses thereof |
| KR101953671B1 (ko) * | 2017-08-21 | 2019-03-04 | 충남대학교산학협력단 | 프로테아좀 억제제를 유효성분으로 함유하는 아토피성 피부질환의 예방, 개선 또는 치료용 조성물 |
| EP3546447A1 (en) * | 2018-03-29 | 2019-10-02 | Heidelberg Pharma GmbH | Synthesis of (2s,3r,4r)-4,5-dihydroxyisoleucine and derivatives |
| CN115006532A (zh) * | 2021-03-05 | 2022-09-06 | 广州医科大学 | 蛋白酶体抑制剂的应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5276182A (en) * | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
| DE4039602A1 (de) * | 1990-12-12 | 1992-06-17 | Bauer Kurt Heinz Prof Dr | Pharmazeutische formulierungen |
| KR100221695B1 (ko) * | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
| US5653962A (en) * | 1991-12-12 | 1997-08-05 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
| CA2149150C (en) * | 1992-11-27 | 2000-08-01 | David R. Carver | Injectable taxol composition with improved stability |
| AU676721B2 (en) | 1993-02-10 | 1997-03-20 | Dana-Farber Cancer Institute | Role of ATP-ubiquitin-dependent proteolysis in MHC-1 restricted antigen presentation and inhibitors thereof |
| US5654286A (en) * | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
| PL177323B1 (pl) * | 1993-10-01 | 1999-10-29 | Syntex Inc | Kompozycja farmaceutyczna zawierająca mykofenolan mofetylu lub kwas mykofenolowy i sposób wytwarzania kompozycji farmaceutycznej zawierającej mykofenolan mofetylu lub kwas mykofenolowy |
| US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| IE80468B1 (en) * | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6335358B1 (en) * | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
| US6838477B2 (en) * | 1995-04-12 | 2005-01-04 | President And Fellows Of Harvard College | Lactacystin analogs |
| US5653987A (en) * | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
| US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| US5667809A (en) * | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
| US5874443A (en) * | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
| US5886210A (en) * | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
| US6271199B2 (en) | 1997-02-15 | 2001-08-07 | Millennium Pharmaceuticals, Inc. | Treatment of infarcts |
| WO1998041648A2 (en) | 1997-03-20 | 1998-09-24 | Variagenics, Inc. | Target genes for allele-specific drugs |
| US5922683A (en) * | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
| DE69809063T2 (de) | 1997-08-04 | 2003-06-12 | Nihon Nohyaku Co., Ltd. | Aryloxyanilin-derivate |
| US6133308A (en) * | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
| NZ503169A (en) | 1997-08-15 | 2001-12-21 | Millennium Pharm Inc | Synthesis of clasto-lactacystin beta-lactone whereupon the process relies upon a stereoselective addition of a formyl amide to an oxazoline |
| US20010051654A1 (en) * | 1997-09-25 | 2001-12-13 | Elliott Peter J. | Treatment of inflammatory and autoimmune diseases |
| AU9580098A (en) | 1997-09-25 | 1999-04-12 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
| CA2219867A1 (en) | 1997-10-31 | 1999-04-30 | Jiangping Wu | The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
| EP2201945B1 (en) * | 1997-11-21 | 2013-03-06 | Purdue Neuroscience Company | Use of substituted 2-aminoacetamides for treating or ameliorating anxiety |
| US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| IL137974A0 (en) * | 1998-03-26 | 2001-10-31 | Shionogi & Co | Indole derivatives having antiviral activity |
| US6509331B1 (en) * | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| AU762373B2 (en) * | 1998-10-20 | 2003-06-26 | Millennium Pharmaceuticals, Inc. | Method for monitoring proteasome inhibitor drug action |
| FR2784988B1 (fr) * | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU1930900A (en) | 1998-12-04 | 2000-06-26 | University Of Maryland Biotechnology Institute | Use of protease inhibitors to modulate cellular pathways, immunity and therapiesassociated therewith |
| US20020049157A1 (en) | 1999-08-25 | 2002-04-25 | Jiangping Wu | Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
| ES2272558T3 (es) | 2000-10-12 | 2007-05-01 | Viromics Gmbh | Inhibidores del proteasoma para el tratamiento de infecciones causadas por virus de la hepatitis. |
| ES2402045T3 (es) | 2000-11-16 | 2013-04-26 | The Regents Of The University Of California | Taxón de actionomiceto marino para el descubrimiento de fármacos y de productos de fermentación |
| WO2003084551A1 (de) | 2002-04-05 | 2003-10-16 | Viromics Gmbh | Mittel zur behandlung von flaviviridae-infektionen |
| US7176232B2 (en) * | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
| US7179834B2 (en) * | 2002-06-24 | 2007-02-20 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
| AU2003249930A1 (en) | 2002-07-03 | 2004-01-23 | Charite - Universitatsmedizin Berlin | Proteaseome inhibitors for the treatment of herpesviridae infected individuals |
| WO2004043374A2 (en) | 2002-11-06 | 2004-05-27 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating cancer using proteasome inhibitors |
| KR20050098928A (ko) * | 2003-02-14 | 2005-10-12 | 바이엘 헬스케어 아게 | 치환된 헤테로사이클 |
| JP2007523862A (ja) | 2003-06-20 | 2007-08-23 | ネレアス ファーマシューティカルズ インコーポレイテッド | 癌、炎症及び感染性疾患の治療のための、[3.2.0]複素環式化合物およびそれらの類縁体の使用 |
| US8217072B2 (en) | 2003-06-20 | 2012-07-10 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
| US7371875B2 (en) * | 2004-03-12 | 2008-05-13 | Miikana Therapeutics, Inc. | Cytotoxic agents and methods of use |
| WO2005099687A2 (en) | 2004-04-09 | 2005-10-27 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
| US7183417B2 (en) * | 2004-04-09 | 2007-02-27 | President And Fellows Of Harvard College | Simple stereocontrolled synthesis of salinosporamide A |
| US7276530B2 (en) | 2004-04-30 | 2007-10-02 | Nereus Pharmaceuticals, Inc. | [3.2.0] Heterocyclic compounds and methods of using the same |
| US7579371B2 (en) * | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
| US20060264495A1 (en) * | 2004-04-30 | 2006-11-23 | Michael Palladino | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
| CN103230394B (zh) | 2004-12-03 | 2016-04-20 | 达纳-法伯癌症研究公司 | 治疗肿瘤性疾病的化合物及其用途 |
| US20060287520A1 (en) | 2005-05-16 | 2006-12-21 | Danishefsky Samuel J | Synthesis of salinosporamide A and analogues thereof |
| WO2007030662A1 (en) | 2005-09-09 | 2007-03-15 | Nereus Pharmaceuticals, Inc. | Biosynthesis of salinosporamide a and its analogs |
| DE102005046344A1 (de) * | 2005-09-28 | 2007-03-29 | Saltigo Gmbh | Verfahren zur Kupplung von Benzylaminen mit Halogenaromaten |
| CA2628110A1 (en) * | 2005-11-04 | 2007-05-18 | The Regents Of The University Of California | Methods of sensitizing cancer to therapy-induced cytotoxicity |
| GB0605217D0 (en) | 2006-03-15 | 2006-04-26 | Novartis Ag | Method and compositions for assessing acute rejection |
| NZ596653A (en) | 2006-04-06 | 2012-10-26 | Nereus Pharmaceuticals Inc | Total synthesis of salinosporamide a and analogs thereof |
| US8088923B2 (en) | 2006-07-07 | 2012-01-03 | The Texas A&M University System | Cyclic-fused beta-lactones and their synthesis |
| WO2008137780A2 (en) | 2007-05-04 | 2008-11-13 | Nereus Pharmaceuticals, Inc. | Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
| US8394816B2 (en) | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
| EP2088205A1 (en) | 2008-02-11 | 2009-08-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | PSMB10: A diagnosis marker and therapeutic target of chronic rejection. |
| BRPI0909661A2 (pt) | 2008-03-07 | 2015-08-11 | Nereus Pharmaceuticals Inc | Composto e métodos de síntese química e de formação ou preparação de compostos |
| US7910616B2 (en) | 2008-05-12 | 2011-03-22 | Nereus Pharmaceuticals, Inc. | Proteasome inhibitors |
-
2004
- 2004-06-18 JP JP2006517404A patent/JP2007523862A/ja not_active Withdrawn
- 2004-06-18 WO PCT/US2004/019543 patent/WO2005002572A2/en not_active Ceased
- 2004-06-18 CA CA2532066A patent/CA2532066C/en not_active Expired - Lifetime
- 2004-06-18 NZ NZ544588A patent/NZ544588A/en not_active IP Right Cessation
- 2004-06-18 EP EP04776757A patent/EP1638552B1/en not_active Expired - Lifetime
- 2004-06-18 MX MXPA05013982A patent/MXPA05013982A/es not_active Application Discontinuation
- 2004-06-18 US US10/871,368 patent/US20050049294A1/en not_active Abandoned
- 2004-06-18 BR BRPI0411677-1A patent/BRPI0411677A/pt not_active IP Right Cessation
- 2004-06-18 AT AT04776757T patent/ATE499934T1/de not_active IP Right Cessation
- 2004-06-18 AU AU2004253478A patent/AU2004253478A1/en not_active Abandoned
- 2004-06-18 KR KR1020057024503A patent/KR20060026052A/ko not_active Ceased
- 2004-06-18 CN CN2010102534518A patent/CN102151261A/zh active Pending
- 2004-06-18 DE DE602004031614T patent/DE602004031614D1/de not_active Expired - Lifetime
-
2005
- 2005-12-20 IL IL172705A patent/IL172705A/en active IP Right Grant
-
2008
- 2008-06-10 US US12/136,688 patent/US8168803B2/en not_active Expired - Lifetime
-
2011
- 2011-10-28 JP JP2011238014A patent/JP2012031198A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NZ544588A (en) | 2010-06-25 |
| EP1638552A2 (en) | 2006-03-29 |
| BRPI0411677A (pt) | 2006-08-29 |
| DE602004031614D1 (de) | 2011-04-14 |
| JP2012031198A (ja) | 2012-02-16 |
| JP2007523862A (ja) | 2007-08-23 |
| MXPA05013982A (es) | 2006-05-25 |
| KR20060026052A (ko) | 2006-03-22 |
| US8168803B2 (en) | 2012-05-01 |
| IL172705A0 (en) | 2006-04-10 |
| AU2004253478A1 (en) | 2005-01-13 |
| CA2532066A1 (en) | 2005-01-13 |
| EP1638552B1 (en) | 2011-03-02 |
| US20090182027A1 (en) | 2009-07-16 |
| WO2005002572A2 (en) | 2005-01-13 |
| US20050049294A1 (en) | 2005-03-03 |
| IL172705A (en) | 2017-06-29 |
| CN102151261A (zh) | 2011-08-17 |
| WO2005002572A3 (en) | 2005-05-12 |
| CA2532066C (en) | 2015-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004031614D1 (de) | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs | |
| EA200601799A1 (ru) | Гидразидсодержащие соединения - ингибиторы cftr и их применение | |
| BRPI0418939A (pt) | derivados de nicotinamida e sua utilização como agentes terapêuticos | |
| CY1118651T1 (el) | Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη | |
| ATE412646T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
| DE60124085D1 (de) | Pde-v hemmer zur behandlung von morbus parkinson | |
| DE60227658D1 (de) | Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| DE60303238D1 (de) | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten | |
| EA200501820A1 (ru) | Терапевтические средства для лечения боли | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| WO2006060809A3 (en) | Methods of using [3.2.0] heterocyclic compounds and analogs thereof | |
| ATE456955T1 (de) | Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen | |
| EP1543158A4 (en) | REGULATED APTAMER THERAPEUTICS | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| ATE446102T1 (de) | Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii | |
| CY1107985T1 (el) | Ccr1 ανταγωνιστες για την αγωγη μεταξυ αλλων απομυελινωτικης φλεγμονωδους νοσου | |
| ATE424824T1 (de) | Verfahren zur verhütung oder behandlung von herzarrhythmie | |
| EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
| CY1119257T1 (el) | Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda) | |
| EA200700407A1 (ru) | Производные хиназолина и их использования при лечении тромбоцитемии | |
| ATE520691T1 (de) | Shp-2-hemmer, pharmazeutische zusammensetzung damit und ihre verwendung zur behandlung phosphatase-vermittelter erkrankungen | |
| ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| DE60005952D1 (de) | Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten | |
| EA200701017A1 (ru) | Применение рибозы-цистеина для лечения гипоксии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |